Novel Yunaconitine Derivatives as Protein Tyrosine Phosphatase 1B Inhibitors and Radical Scavenger: Design, Synthesis, in Vitro Cellular Evaluation, and Molecular Docking Study

This is the authors' abstract. We don't add key points for this paper.

Diabetes and oxidative stress are serious threats to human health and well-being. Protein tyrosine phosphatase 1B (PTP1B) and oxidative stress are important targets for managing diabetes. In this work, a series of new Yunaconitine derivatives (1-25) were synthesized and characterized; their inhibitory activity on PTP1B was first evaluated. Among them, derivatives 2 and 25 showed remarkable bioactivities with half-maximal inhibitory concentration values of 7.724 and 8.981 µM, respectively. Furthermore, derivatives 2 and 25 were evaluated for their free radical scavenging activity in vitro. Notably, derivative 25 exhibited significant free radical scavenging: 50% effective concentration = 58.76 µM. In addition, molecular docking analysis indicated that derivative 25 has a binding affinity for PTP1B and nicotinamide adenine dinucleotide phosphate-oxidase, with a binding energy of -5.03 and -2.66 kcal/mol, respectively. These results suggested that derivative 25 possesses great potential as a dual-target (PTP1B Inhibitor and radical scavenger) drug candidate for the treatment of diabetes.